The price adjustment plan of Chinese patent medicine is expected to be finalized in March, with a decrease of 15% for some drugs

March 12: the price adjustment plan of "varieties of Chinese patent medicine in the national medical insurance catalog" is expected to come to an end within this month On March 12, according to China Securities News, the drug price evaluation center of the national development and Reform Commission reviewed the list of the last batch of Chinese patent medicines to be reduced in price on March 7 Around March 20, the drug price department of the national development and Reform Commission will organize a seminar to finalize the price adjustment plan According to people familiar with the matter, in this round of price adjustment plan, Chinese patent medicine with higher price before will usher in a decrease of about 15%, which may also be the "ceiling" of this round of price reduction The drugs with relatively low price are to be selected into the catalogue of low-cost drugs, and the enterprise will make its own price within the range of 3-5 yuan In response, Meng lining, a senior pharmaceutical investor, said the price cut was much more moderate than the previous market expected 25% drop In response to the above price adjustment plan, executives of several listed companies said that even if anti-tumor and cardiovascular and cerebrovascular drugs were used to "sacrifice the flag" in this round of price adjustment, it would not impact the company's performance However, industry analysts said that for small manufacturers and distributors in the industry of Chinese patent medicine, especially for Chinese herbal medicine manufacturers in the upper reaches of Chinese patent medicine, the days are obviously a little sad Analysts said that due to the impact of the economic environment, the difficulty of the operation of traditional Chinese medicine is increasing, the supply is excessive, the labor cost is increasing, and the competition is fierce Many problems lead to the difficulties of dealers in the operation of traditional Chinese medicine The price reduction of proprietary Chinese medicine will further reduce the profits of its APIs, force small and medium-sized manufacturers to withdraw from the market, and help large enterprises take the opportunity to improve the industry concentration.